CONFERENCE PROGRAM

FRIDAY, SEPTEMBER 21

3:00 p.m.-7:00 p.m.  REGISTRATION
Foyer

6:00 p.m.-8:10 p.m.  WELCOME AND KEYNOTE LECTURES
Salon A-E

Session Chair: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA

6:00 p.m.-6:10 p.m.  Welcome from Cochairs
Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA

6:10 p.m.-6:20 p.m.  Welcome from Lead Supporters
Kerri Kaplan, Lustgarten Foundation, Woodbury, NY
Julie M. Fleshman, Pancreatic Cancer Action Network, Manhattan Beach, CA

6:20 p.m.-7:00 p.m.  Precision medicine for pancreas cancer: New approaches from old
Ben Z. Stanger, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA

7:00 p.m.-7:40 p.m.  Designing clinical trials in pancreatic cancer: Challenges and innovations
Andrew H. Ko, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

7:40 p.m.-8:10 p.m.  Outcomes of surveillance and treatment of high-risk individuals
Marcia Irene (Mimi) Canto, Johns Hopkins University, Baltimore, MD

8:15 p.m.-10:00 p.m.  OPENING RECEPTION
Salon F-K

SATURDAY, SEPTEMBER 22

7:30 a.m.-8:30 a.m.  BREAKFAST AND NETWORKING ROUNDTABLES
Salon F-K

Andrew Aguirre, Dana-Farber Cancer Institute, Boston, MA
Mariano Barbacid, Spanish National Cancer Research Center, Madrid, Spain
Marcia Irene (Mimi) Canto, Johns Hopkins University, Baltimore, MD
Eugene Koay, The University of Texas MD Anderson Cancer Center, Houston, TX
Steven D. Leach, Dartmouth Norris Cotton Cancer Center, Lebanon, NH
Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, MA
Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN
Michael H. Rosenthal, Dana-Farber Cancer Institute, Boston, MA
8:30 a.m.-10:00 a.m.  PLENARY SESSION 1: IMAGING/DIAGNOSTICS  
Salon A-E

Session Chair: Julie L. Sutcliffe, University of California, Davis, Davis, CA

8:30 a.m.-9:00 a.m.  Pancreas imaging 2018: MDCT, 3D rendering, and deep learning  
Elliot K. Fishman, Johns Hopkins Hospital, Baltimore, MD

9:00 a.m.-9:30 a.m.  Immunologic properties of biophysical subtypes of pancreatic cancer: Implications for therapeutic selection  
Eugene Koay, The University of Texas MD Anderson Cancer Center, Houston, TX

9:30 a.m.-10:00 a.m.  Using artificial intelligence to extract latent biomarkers from clinical imaging of the pancreas  
Michael H. Rosenthal, Dana-Farber Cancer Institute, Boston, MA

10:00 a.m.-10:30 a.m.  BREAK  
Foyer

10:30 a.m.-12:30 p.m.  PLENARY SESSION 2: THE CHANGING PRACTICE OF GENETIC TESTING  
Salon A-E

Session Chair: Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN

10:30 a.m.-11:00 a.m.  Risk estimates for pancreatic cancer predisposition genes  
Fergus J. Couch, Mayo Clinic, Rochester, MN

11:00 a.m.-11:30 a.m.  Therapeutic implications of germline variants in pancreatic cancer  
Maev Lowery, Trinity College Dublin, Dublin, Ireland

11:30 a.m.-12:00 p.m.  Genetic predisposition to pancreatic cancer: Who should be tested, and how?  
Elena M. Stoffel, University of Michigan, Ann Arbor, MI

12:00 p.m.-12:30 p.m.  Identification and management of healthy individuals with pancreatic cancer gene mutations  
Sapna Syngal, Dana-Farber Cancer Institute, Boston, MA

12:30 p.m.-3:00 p.m.  POSTER SESSION A / LUNCH  
Salon F-K

3:15 p.m.-4:45 p.m.  PLENARY SESSION 3: BLOOD-BASED EARLY DETECTION  
Salon A-E

Session Chair: Marcia Irene (Mimi) Canto, Johns Hopkins University, Baltimore, MD

3:15 p.m.-3:45 p.m.  Multi-analyte blood test for the detection of cancer  
Nickolas Papadopoulos, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
CONFERENCE PROGRAM

3:45 p.m.-4:15 p.m.  Advancing a plasma marker panel to detect pancreatic ductal adenocarcinoma  
Kenneth S. Zaret, University of Pennsylvania, Philadelphia, PA

4:15 p.m.-4:45 p.m.  Multiplex enrichment and detection of KRAS mutations in liquid biopsy samples using digital droplet preamplification  
Erica D. Pratt, University of Minnesota, Minneapolis, MN

4:45 p.m.-5:00 p.m.  BREAK  
Foyer

5:00 p.m.-6:30 p.m.  PLENARY SESSION 4: IMMUNOLOGY AND IMMUNOTHERAPY  
Salon A-E  
Session Chair: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA

5:00 p.m.-5:30 p.m.  Immunotherapy strategies in PDAC  
Manuel Hidalgo

5:30 p.m.-6:00 p.m.  Decoding the T cell-antigen landscape of long-term pancreatic cancer survivors  
Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, NY

6:00 p.m.-6:30 p.m.  Innate and adaptive immunity in the tumor microenvironment of pancreas cancer  
David C. Linehan, University of Rochester, Rochester, NY

6:30 p.m.-  EVENING OFF / DINNER ON OWN

SUNDAY, SEPTEMBER 23

7:30 a.m.-8:30 a.m.  BREAKFAST AND NETWORKING ROUNDTABLES  
Salon F-K  
Andrew Aguirre, Dana-Farber Cancer Institute, Boston, MA  
Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, NY  
Kerri Kaplan, Lustgarten Foundation, Woodbury, NY  
Eugene Koay, The University of Texas MD Anderson Cancer Center, Houston, TX  
Steven D. Leach, Dartmouth Norris Cotton Cancer Center, Lebanon, NH  
David C. Linehan, University of Rochester, Rochester, NY  
Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, MA  
Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN
8:30 a.m.-10:00 a.m.  PLENARY SESSION 5: TUMOR MICROENVIRONMENT
Salon A-E

Session Chair: Ronald M. Evans, Salk Institute for Biological Studies, La Jolla, CA

8:30 a.m.-9:00 a.m.  The tumor microenvironment of primary and metastatic pancreatic adenocarcinoma: Similarities, differences, and response to treatment
Michael A. Hollingsworth, UNMC Eppley Institute for Research in Cancer, Omaha, NE

9:00 a.m.-9:30 a.m.  Fibroblast heterogeneity in pancreatic cancer
David A. Tuveson, Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, NY

9:30 a.m.-10:00 a.m.  Exploiting the complex stromal biology of pancreas cancer
Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, WA

10:00 a.m.-10:30 a.m.  BREAK
Foyer

10:30 a.m.-12:30 p.m.  PLENARY SESSION 6: RAS / SIGNALING / ONCOGENES
Salon A-E

Session Chair: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA

10:30 a.m.-11:00 a.m.  Engineered exosomes for precision therapy of pancreatic cancer
Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, TX

11:00 a.m.-11:30 a.m.  Treatment of oncogenic activation of ERK in human cancer
Neal Rosen, Memorial Sloan Kettering Cancer Center, New York, NY

11:30 a.m.-12:00 p.m.  Targeting cancer-specific vulnerabilities
Ronald A. DePinho, The University of Texas MD Anderson Cancer Center, Houston, TX

12:00 p.m.-12:30 p.m.  Complete regression of advanced pancreatic ductal adenocarcinomas in genetically engineered mice upon combined inhibition of EGFR and c-RAF signaling pathways
Mariano Barbacid, Spanish National Cancer Research Center, Madrid, Spain

12:30 p.m.-2:30 p.m.  FREE TIME / LUNCH ON OWN

2:45 p.m.-4:45 p.m.  PLENARY SESSION 7: METABOLISM AND METABOLOMICS
Salon A-E

Session Chair: Ronald M. Evans, Salk Institute for Biological Studies, La Jolla, CA

2:45 p.m.-3:15 p.m.  Epigenetic control of PDA genomic networks
Ronald M. Evans

3:15 p.m.-3:45 p.m.  Title to be announced
Nabeel M. Bardeesy, Massachusetts General Hospital Cancer Center, Boston, MA
CONFERENCE PROGRAM

3:45 p.m.-4:15 p.m.  Targeting cysteine metabolism in pancreatic cancer
Kenneth P. Olive, Columbia University Irving Comprehensive Cancer Center, New York, NY

4:15 p.m.-4:45 p.m.  Metabolic vulnerabilities—targeting oxidative phosphorylation
Giulio F. Draetta, The University of Texas MD Anderson Cancer Center, Houston, TX

5:00 p.m.-5:40 p.m.  SPOTLIGHT ON PROFERRED PAPERS
Salon A-E

5:00 p.m.-5:08 p.m.  Post-translational O GlcNAcylation of SOX2 controls its tumor initiation properties in pancreatic cancer*
Nikita Sharma, University of Miami, Miami, FL

5:08 p.m.-5:16 p.m.  Identification of functional heterogeneity of fibroblasts and their impact on riot immunity in pancreatic cancer*
Josephine Darpolor, The University of Texas MD Anderson Cancer Center, Houston, TX

5:16 p.m.-5:24 p.m.  Lysyl oxidases suppress pancreatic cancer progression by inhibiting focal adhesion kinase signaling*
Mario Shields, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

5:24 p.m.-5:32 p.m.  PDAC development and progression is dependent upon SHP2*
Michael VanSaun, University of Miami, Miami, FL

5:32 p.m.-5:40 p.m.  RNA profiling and the impact of current classifiers on survival in patients receiving combination chemotherapy on the COMPASS trial*
Grainne O’Kane, Princess Margaret Cancer Centre, Toronto, ON, Canada

5:45 p.m.-8:00 p.m.  POSTER SESSION B / RECEPTION
Salon F-K

8:00 p.m.-  EVENING OFF / DINNER ON OWN

MONDAY, SEPTEMBER 24

7:30 a.m.-8:30 a.m.  BREAKFAST
Salon F-K

*Short talk from proffered abstract
8:30 a.m.-10:00 a.m.  PLENARY SESSION 8: PRECISION MEDICINE  
Salon A-E  
Session Chair: Steven D. Leach, Dartmouth Norris Cotton Cancer Center, Lebanon, NH  

8:30 a.m.-9:00 a.m.  Genomic and functional profiling of advanced pancreatic cancer to enable precision medicine  
Andrew Aguirre, Dana-Farber Cancer Institute, Boston, MA  

9:00 a.m.-9:30 a.m.  Using pancreatic organoids to model, detect, and treat cancer  
Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, MA  

9:30 a.m.-10:00 a.m.  Altered mRNA splicing by mutant p53 activates oncogenic RAS signaling in pancreatic cancer  
Lusia Escobar-Hoyos, Memorial Sloan Kettering Cancer Center, New York, NY  

10:00 a.m.-10:15 a.m.  BREAK  
Foyer  

10:15 a.m.-11:45 a.m.  PLENARY SESSION 9: LOCAL-REGIONAL THERAPIES/MANAGEMENT OF LOCAL DISEASE  
Salon A-E  
Session Chair: Susan Tsai, Medical College of Wisconsin, Milwaukee, WI  

10:15 a.m.-10:45 a.m.  Pancreas SBRT: Ablation versus immune potentiation  
Joseph M. Herman, The University of Texas MD Anderson Cancer Center, Houston, TX  

10:45 a.m.-11:15 a.m.  Why operable pancreatic cancer is the best model for translational research: Treatment sequencing, assessment of response, and results with innovative multimodality therapy  
Douglas B. Evans, Medical College of Wisconsin, Milwaukee, WI  

11:15 a.m.-11:45 a.m.  New directions in adjuvant and neoadjuvant therapy for resectable pancreas ductal adenocarcinoma  
Eileen O’Reilly, Memorial Sloan Kettering Cancer Center, New York, NY  

11:45 a.m.-12:45 p.m.  PANEL DISCUSSION ON CLINICAL TRIALS  
Salon A-E  
Moderator: Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN  

Panelists  
James L. Abbruzzese, Duke University Medical Center, Durham, NC  
Wen Wee Ma, Mayo Clinic, Rochester, MN  
Lynn M. Matrisian, Pancreatic Cancer Action Network, Manhattan Beach, CA  
Diane M. Simeone, New York University, New York, NY  
Andrea Wang-Gillam, Washington University in St.Louis, St. Louis, MO  

12:45 p.m.  DEPARTURE